Ultragenyx Pharmaceutical Inc.
RARE
$39.64
$0.300.76%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 0.10% | -1.46% | 22.90% | -38.55% | 22.84% |
| Total Depreciation and Amortization | 3.68% | -1.18% | 0.19% | 7.63% | 14.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.13% | -8.43% | 8.42% | 52.73% | -44.11% |
| Change in Net Operating Assets | -26.20% | 88.46% | 129.20% | -521.07% | 375.14% |
| Cash from Operations | -18.67% | 12.95% | 59.65% | -127.32% | 28.82% |
| Capital Expenditure | 59.55% | 19.51% | 37.43% | -100.69% | 56.70% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 137.75% | -537.70% | -35.92% | 192.63% | -255.05% |
| Cash from Investing | 137.29% | -554.89% | -35.87% | 188.24% | -266.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -23.67% | -98.92% | -- | -- | 1,210.18% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | 11,968.97% | 200.00% | -- | -- |
| Cash from Financing | -71.49% | -97.10% | 663,787.93% | -100.02% | 1,210.18% |
| Foreign Exchange rate Adjustments | -293.96% | 296.76% | 4.57% | -161.56% | 254.05% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.26% | -189.71% | 479.16% | -168.92% | 584.47% |
